Description
CONTROLIP®-TRILIPIX® is indicated as a supplement to the diet:
Monotherapy:
– Severe hypertriglyceridaemia with or without low HDL-cholesterol.
– Mixed hyperlipidemia when a statin is contraindicated or not well tolerated.
Co-administration:
– Mixed hyperlipidemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL-cholesterol are not adequately controlled with statin alone.
No incremental benefit of CONTROLIP®-TRILIPIX® on cardiovascular morbidity and mortality has been established greater than that demonstrated for statin monotherapy.
Fenofibrate in a dose equivalent to 135 mg of CONTROLIP®-TRILIPIX® was not shown to reduce morbidity and mortality from coronary heart disease in a large, randomized, controlled study of patients with type 2 diabetes mellitus.
Reviews
There are no reviews yet.